Access to different MHT preparations is essential to optimise treatment and meet women’s needs. However, in various parts of the world, lack of availability of licenced MHT products, commercial discontinuation of products and manufacturing and supply shortages impact
on such access.

Please click on the link below to see the full article by our Chairman, Haitham Hamoda published in Maturitas this month.

Availabilty of menopausal hormone therapy products worldwide